Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Vertex (VRTX) PT Raised to $459 at Morgan Stanley
February 11, 2025 7:10 AM ESTMorgan Stanley analyst Terence Flynn raised the price target on Vertex (NASDAQ: VRTX) to $459.00 (from $450.00) while maintaining a Equalweight rating.
The analyst comments "VRTX posted a 4Q beat and first time 2025 Rev/expense guidance bracketed consensus. Looking ahead the focus is on... More
Vertex Pharma (VRTX) Misses Q4 EPS by 4c, Revenues Beat
February 10, 2025 4:04 PM ESTVertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $3.98, $0.04 worse than the analyst estimate of $4.02. Revenue for the quarter came in at $2.91 billion versus the consensus estimate of $2.79 billion.
GUIDANCE:
Vertex Pharma sees FY2025 revenue of $11.75-12 billion, versus the consensus of... More
